BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 11039898)

  • 41. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
    Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
    Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
    Rodriguez-Puebla ML; LaCava M; Gimenez-Conti IB; Johnson DG; Conti CJ
    Oncogene; 1998 Oct; 17(17):2251-8. PubMed ID: 9811455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels.
    Jiang H; Karnezis AN; Tao M; Guida PM; Zhu L
    Oncogene; 2000 Aug; 19(34):3878-87. PubMed ID: 10951581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter.
    Stiegler P; De Luca A; Bagella L; Giordano A
    Cancer Res; 1998 Nov; 58(22):5049-52. PubMed ID: 9823308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rb dephosphorylation and suppression of E2F activity in human breast tumor cells exposed to a pharmacological concentration of estradiol.
    Gewirtz DA; Di YM; Randolph JK; Jain PT; Valerie K; Bullock S; Nath N; Chellappan SP
    Arch Biochem Biophys; 2001 Apr; 388(2):243-52. PubMed ID: 11368161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor suppressor proteins as regulators of cell differentiation.
    Li ZR; Hromchak R; Mudipalli A; Bloch A
    Cancer Res; 1998 Oct; 58(19):4282-7. PubMed ID: 9766653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.
    Tomoda K; Kubota Y; Kato J
    Nature; 1999 Mar; 398(6723):160-5. PubMed ID: 10086358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
    Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
    Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation.
    Vairo G; Soos TJ; Upton TM; Zalvide J; DeCaprio JA; Ewen ME; Koff A; Adams JM
    Mol Cell Biol; 2000 Jul; 20(13):4745-53. PubMed ID: 10848600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Control of E2F activity by p21Waf1/Cip1.
    Delavaine L; La Thangue NB
    Oncogene; 1999 Sep; 18(39):5381-92. PubMed ID: 10498892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
    Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
    Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
    Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
    Mateyak MK; Obaya AJ; Sedivy JM
    Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis.
    Pascale RM; Simile MM; De Miglio MR; Muroni MR; Calvisi DF; Asara G; Casabona D; Frau M; Seddaiu MA; Feo F
    Hepatology; 2002 Jun; 35(6):1341-50. PubMed ID: 12029619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
    Luo Q; Li J; Cenkci B; Kretzner L
    Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Cdk inhibiting proteins].
    Tomoda K; Kato J
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1407-13. PubMed ID: 9309133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional roles of E2F in cell cycle regulation.
    Fan J; Bertino JR
    Oncogene; 1997 Mar; 14(10):1191-200. PubMed ID: 9121768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Histone deacetylase and retinoblastoma protein].
    Magnaghi-Jaulin L; Groisman R; Naguibneva I; Robin P; Trouche D; Harel-Bellan A
    Bull Cancer; 1998 Jul; 85(7):606-7. PubMed ID: 9752266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
    Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts.
    Hara E; Uzman JA; Dimri GP; Nehlin JO; Testori A; Campisi J
    Dev Genet; 1996; 18(2):161-72. PubMed ID: 8934878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.